4.7 Article

Outcome modeling with CRLF2, IKZF1, JAK and minimal residual disease Study in pediatric acute lymphoblastic leukemia: a Children's Oncology Group

Journal

BLOOD
Volume 119, Issue 15, Pages 3512-3522

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-11-394221

Keywords

-

Categories

Funding

  1. NIH [U10 CA98543, U10 CA98413, U24 CA114766]
  2. NCI [U01 CA114762, GO 5RC2 CA14852902]
  3. Leukemia and Lymphoma Society SCOR [7388-06 (PI, CW), R01 CA086011]

Ask authors/readers for more resources

As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor ALL classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R) and minimal residual disease (MRD) in 1,061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. While very high CRLF2 expression was found in 17.5% of cases (19% of HR, 16.2% of SR), only 51.4% of high CRLF2-expressors had CRLF2 genomic lesions. The mechanism underlying elevated CRLF2 expression in cases lacking known genomic lesions remains to be determined. All CRLF2 genomic lesions and virtually all JAK mutations were found in high CRLF2- expressors, while IKZF1 deletions/mutations were distributed across the full cohort. In multivariate analyses, NCI risk group, MRD, high CRLF2 expression (each P<.001), and IKZF1 lesions (P=.037) were associated with relapse-free survival (RFS). Within HR ALL, only MRD (P<.001) and CRLF2 expression (P<.001) predicted a poorer RFS; no difference was seen between cases with or without CRLF2 genomic lesions. Thus, high CRLF2 expression is associated with a very poor outcome in high, but not standard-risk ALL. This study is registered at NCT00005596, www.ClinicalTrials.gov and NCT00005603, www.ClinicalTrials.gov.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available